Key result
Intravenous infusion of GLP-1 improved global left ventricular ejection fraction at peak dobutamine stress compared with control (77.0% vs 70.8%, P<0.0001) in patients with coronary artery disease.
Why the study?
Does intravenous GLP-1 infusion prevent ischaemic left ventricular dysfunction during dobutamine stress echocardiography in patients with coronary artery disease?
Population
14 patients with coronary artery disease and good left ventricular function awaiting revascularisation
Comparison
Intravenous infusion of glucagon-like peptide-1… vs Control dobutamine stress echocardiography scan…
Design
RCT, randomised order (crossover design)
Follow-up
30 minutes into recovery post-stress
Authors
Loading...
May mitigate ischaemic LV dysfunction during stress in CAD; hypothesis-generating, leaves clinical adoption open pending RCTs.
RCT (n=14)
Crossover
Does intravenous GLP-1 infusion prevent ischaemic left ventricular dysfunction during dobutamine stress echocardiography in patients with coronary artery disease?
Absolute Event Rate: 77% vs 70.8%
p-value: p=<0.0001
Intravenous GLP-1 infusion mitigates ischaemic LV dysfunction and post-ischaemic stunning during dobutamine stress in patients with CAD.
Read et al. (2011) conducted an RCT in Coronary artery disease (n=14). Glucagon-like peptide-1 (GLP-1) vs. Control scan was evaluated on Global and regional wall left ventricular function assessed using tissue Doppler imaging at rest, peak stress and 30 min into recovery (p=<0.0001). Intravenous infusion of GLP-1 improved global left ventricular ejection fraction at peak dobutamine stress compared with control (77.0% vs 70.8%, P<0.0001) in patients with coronary artery disease.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: